Enabling the Rise of a CRISPR World
As the World Debates Genome Editing Regulations, the Scientific Community Continues the Push to Democratize CRISPR
Single-Cell Cloning Remains a Challenge
Evolving Technologies Help Make It Easier to Meet Regulatory Requirements
Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
Top 10 Biopharma IPOs of January—June 2018
Number of Companies Going Public, and the Amount They Raise, Show Growth
For full access to this article login to GEN Select now.
Managing Biosimilars Is Like Herding Copycats
Developers and Regulators Are Attending to Naming Conventions and Equivalence Testing Assays
- Biosimilars, or copycats of biologic drugs, stray from clearly defined categories. Each biosimilar comes from a unique biomanufacturing environment and, consequently, possesses unique chemical attributes, which may or may not prove to be clinically relevant—most likely not (but worth checking). Moreover, each biosimilar may go its own way, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.